SEC Tracker
Get the app

Adial Pharmaceuticals AZR

Adial Pharmaceuticals (ADIL) has filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational status. The filing highlights the company's progress in advancing its lead drug candidate and ongoing clinical trials, which are critical to Adial's long-term growth and value proposition. Investors will closely monitor this report for insights into the company's near-term prospects and potential catalysts.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when Adial Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  2. Vyome Holdings HIND public float $6M, Jun 30, 2025
  3. Biomerica BMRA public float $7M, Nov 28, 2025
  4. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025